Matches in Nanopublications for { ?s ?p "[In this article entitled How many JAK inhibitors for myelofibrosis we discuss JAK2 as a target, review briefly the benefits to patients with MF of JAK inhibition and highlight some of the differences between the number of JAK inhibitors currently being evaluated.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 2 of
2
with 100 items per page.
- NP1217008.RAvf6Ex6sdB-5TIihpSu3mtLFzbcYiU7P0pI5NKPEEGeE130_assertion description "[In this article entitled How many JAK inhibitors for myelofibrosis we discuss JAK2 as a target, review briefly the benefits to patients with MF of JAK inhibition and highlight some of the differences between the number of JAK inhibitors currently being evaluated.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1217008.RAvf6Ex6sdB-5TIihpSu3mtLFzbcYiU7P0pI5NKPEEGeE130_provenance.
- NP1217011.RAgPR_bGH7cO7ATFTPH-e9qleLKHdlL3-as6zVDSBdCxg130_assertion description "[In this article entitled How many JAK inhibitors for myelofibrosis we discuss JAK2 as a target, review briefly the benefits to patients with MF of JAK inhibition and highlight some of the differences between the number of JAK inhibitors currently being evaluated.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1217011.RAgPR_bGH7cO7ATFTPH-e9qleLKHdlL3-as6zVDSBdCxg130_provenance.